StockData

Dianthus Therapeutics vs Korsana Biosciences

DNTH and KRSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DNTH and KRSA compare

Dianthus Therapeutics is the larger company, worth 3.6 times as much as Korsana Biosciences ($5.1B against $1.4B).

Korsana Biosciences scores higher on the StockData Score (8 against 7 for Dianthus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDNTHKRSA
Size and price
Market cap$5.1B$1.4B
Share price$91.81$31.65
Change, 1 year137%218%
Change, 5 years−14.2%−90.3%
Beta (5Y)1.441.41
Employees921
StockData Score
Total score78 (better)
Valuation score00
Growth score01 (better)
Performance score11
Health score66
Dividend score00
Valuation
P/B4.1×3.7× (better)
Growth
Revenue growth, 5Y average–−2.0%
Profitability
Return on equity−22.6% (better)−31.8%
Return on invested capital−22.2%–
Financial health
Debt / equity0.000.00
Current ratio30.02 (better)10.42
Altman Z-score88.13 (better)19.65
Piotroski F-score25 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield−0.01%–
Shareholder yield−0.01%0.00% (better)
Ownership
Held by institutions118%1.6%
Held by insiders9.1%46.5%
Insider net buying, 12 months−$75.1M–
Short interest, % of float18.2%0.69%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.